Goldenwell Biotech, Inc.

What they do

The company holds exclusive licenses to technology and packaging designs for products including Sugar Master and DNA Repair, licensed from Australian Trefoil Health Technologies Pty Ltd and Ji Lin JZY Biotech Inc. Neither licensor is arm's length: Australian Trefoil is controlled by director Li Yang and JZY Biotech is controlled by President/CEO and director Shang Liu. Its product line is built around polypeptide freeze-dried powders, including JI MAI bovine cardiac vascular active peptide. It does not conduct operations at its Solon, Ohio office and only receives mail there.

Revenue drivers

• Nutraceutical and dietary supplement sales — The entire reported business; revenue was $55 in 2025 and $139 in 2024, with cost of revenue of $43 and $75, respectively.
• JI MAI bovine cardiac vascular active peptide — One of five products described in the 10-K; the company states all five have completed marketing analysis, R&D, and parts of production setup, but no commercial sales scale is disclosed.
• Other Goldenwell products (unspecified in excerpt) — The 10-K refers to '5 products' but only JI MAI is described in the excerpt; no revenue is broken out by product, so no product-level size can be determined.

Recent performance

Full-year 2025 revenue was $55, down from $139 in 2024, producing gross profit of $12 versus $64. The 2025 net loss was $296,471, compared with $131,498 in 2024. General and administrative expenses were $113,338 in 2025 versus $123,098 in 2024. Net cash used in operating activities was $22,629 in 2025, versus $123,077 in 2024, and there was no financing cash flow in 2025 after $119,250 in 2024. At June 30, 2026, quarterly revenue was $0.00, total assets were $28,978, total liabilities were $427,173, and stockholders' equity was negative $398,195.

Strategy

Management states its plan of operation for the 12 months following the 10-K is to increase sales of its products. It expects to fund operations through debt or equity offerings, private placements, and continuing financial support from existing stockholders. The company believes cash of $26,775 at December 31, 2025 is adequate to support general operations until at least December 31, 2026. The 10-K notes material hurdles remain before products can be sold commercially, including site location, workshop installation, equipment setup, and workforce training.

Risks

• Going concern — The company states it has little operations or revenues, recurring losses, and substantial doubt about its ability to continue as a going concern absent new capital.
• Negative working capital and accumulating losses — Working capital was negative $343,713 at December 31, 2025, and the net loss widened to $296,471 in 2025 from $131,498 in 2024.
• Related-party licenses — Both exclusive license agreements are with entities controlled by a director and by the President/CEO, respectively, and each was entered into for $10.00 in consideration.
• License expiration and no commercial scale — The Australian Trefoil license term is stated to expire November 15, 2025, and the company has not demonstrated commercial-scale sales of any licensed product.

Outlook

Management says it plans to raise additional funds through debt or equity offerings and to increase product sales, with no guarantee that capital can be raised. It believes existing cash is sufficient for general operations until at least December 31, 2026. The company anticipates substantially greater revenues only if it completes financing and implements its initial business plan. It continues to rely on financing from existing shareholders and private placements.